retatrutide with cagrilintide vs CagriSema: The Battle Nobody's Covering Cagri Peptide With Retatrutide: UK
Description
At the 82nd Golden Globes on Jan
Results from Eli Lilly's Phase 2 trial (Jastreboff et al., New England Journal of Medicine, 2023) reported mean body weight reductions of approximately 1724% over 48 weeks depending on dose, which has generated considerable scientific interest
Tirzepatide is a dual-agonist weight loss drug thats currently on the market
No waiting room
Sci Rep (2016) 6:26859
Facial volume loss is a normal, and treatable, part of the process
